Medical Developments International (ASX:MVP) has delivered its third-quarter performance for the 2026 financial year, marked by a shift to positive cash flow and double-digit revenue growth.
The healthcare company reported a 19% year-on-year revenue surge, reaching $10.5 million, primarily bolstered by the stellar performance of its pain management flagship, Penthrox.
Sales for the inhaler rose to $8.4 million this quarter—a 47% increase—reflecting strong uptake in Australian hospitals and steady expansion across European markets.
The commercial momentum successfully translated into a healthy bottom line, with the company generating $2.5 million in operating cash flow for the period, bringing the year-to-date total to $2.8 million.
MVP maintained a solid balance sheet, closing the quarter with $18.7 million in cash reserves.
The group is now pivoting towards major regulatory milestones in Europe, where Penthrox is already approved in 12 markets.
Following the successful publication of the MAGPIE paediatric study, the company expects to finalise European paediatric label approvals shortly, with a UK green light anticipated by August 2026.
While the core pain management division thrives, the company remains vigilant regarding its respiratory segment, which faced a $1 million decline due to softer US demand.
Additionally, management is actively navigating external headwinds, including US tariffs on respiratory inputs and potential supply chain disruptions stemming from Middle East instability.
At the time of reporting, Medical Developments International’s share price was $0.50.